Related Experiment Video
Updated: May 16, 2026
An Improved and High Throughput Respiratory Syncytial Virus (RSV) Micro-neutralization Assay
Published on: January 26, 2019
Maternal preferences for infant respiratory syncytial virus (RSV) preventives: an Australian discrete choice
Margie Danchin1, Ashleigh Rak2, Sophie Vasiliadis2
1Vaccine Uptake Group, Murdoch Children's Research Institute, 50 Flemington Road, Parkville, Victoria 3052, Australia; Department of Paediatrics, Faculty of Medicine Dentistry and Health Sciences, The University of Melbourne, 50 Flemington Road, Parkville, Victoria 3052, Australia; Department of General Medicine, The Royal Children's Hospital, 50 Flemington Road, Parkville, Victoria 3052, Australia.
Objectives:
Two RSV preventatives, a maternal RSV vaccine and a long-acting monoclonal antibody, were introduced in Australia in 2025. In the year prior to program introduction, we explored maternal acceptability, preferences, awareness and knowledge of disease and provider delivery preferences.
Design:
Discrete Choice Experiment (DCE).
Setting:
Qualitative data from online focus groups informed a national DCE survey.
Participants:
Qualitative data from Australian mothers with a child <2 years was collected through focus groups, identifying key themes for decision-making. The final attributes for the DCE survey included effectiveness, cost, safety, timing, and risk perception of the disease and was administered to 1500 pregnant people and mothers with a child <2 years.
Main Outcome Measures:
The primary outcomes were acceptability and maternal preferences for RSV preventatives and secondary outcomes were maternal awareness/knowledge of RSV and provider delivery preference.
Results:
We found knowledge of the monoclonal antibody and perception of disease severity were low and maternal vaccine decision-making and acceptability of preventatives is strongly influenced by cost, effectiveness and safety. Overall, 51.4% of mothers preferred the maternal vaccine and 24.3% preferred the monoclonal antibody or were 'not sure' and general practitioners (GPs) were the preferred provider for delivery.
Conclusion:
Prior to the introduction of the hybrid RSV prevention program for infants in Australia in February 2025, we found that awareness of disease and RSV preventatives was low and that decision-making was influenced by cost, effectiveness and safety concerns. This study highlights the need for a national RSV implementation strategy and harmonised, Commonwealth-funded RSV program to optimise equitable uptake.
More Related Videos
Related Concept Videos
01:23Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics
Antitussives include codeine, dextromethorphan (Robitussin), and benzonatate (Tessalon). Codeine and dextromethorphan exert their effects centrally by suppressing the cough reflex center in the medulla. Benzonatate operates peripherally within the respiratory tract by anesthetizing...
01:03Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
01:25Transmission-based Precautions II: Airborne and Protective Environment
Airborne precautions:
Use airborne precautions when treating patients known or suspected to have diseases that spread through the air—for example, tuberculosis or measles. These organisms are present in smaller droplets expelled by an infected person and...
01:20Assessment of Ventilation I: Respiratory Rate
A Ventilation assessment is critical for monitoring a patient's health status. Respiration, one of the most accessible vital signs, provides insights into the function of numerous body systems and can indicate serious health issues, such as brainstem injuries from head trauma.
Critical Guidelines for Assessing Ventilation: